https://scholars.lib.ntu.edu.tw/handle/123456789/526907
標題: | Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: A systematic review and meta-analysis | 作者: | Lee S.-H. Chang S.-S. Lee M. Chan R.-C. CHIEN-CHANG LEE |
公開日期: | 2014 | 卷: | 25 | 期: | 3 | 起(迄)頁: | 1131-1139 | 來源出版物: | Osteoporosis International | 摘要: | We aimed to systematically review observational studies evaluating use of bisphosphonates (BPs) and risk of osteonecrosis of jaw (ONJ) or other sites among non-cancer patients. Introduction: PubMed, EMBASE, and Cochrane Library were screened from database inception to Dec 2012. Methods: Two reviewers independently identified cohort and case-control studies evaluating the use of oral or intravenous (IV) BPs and the risk of ONJ and extracted the characteristics of the studies and risk estimates. Pooled estimates of odds ratios and 95 % confidence intervals (CI) were derived by random effects meta-analysis. Subgroup analyses were carried according to patients' characteristics and route of BP use. Results: We identified 12 studies, including 2,652 cases and 1,571,997 controls. Use of BPs was associated with a significantly increased risk of ONJ or ON of other sites [odds ratio (OR) 2.32; 95 % CI 1.38-3.91; I 2 = 91 %]. The summary OR was 2.91 (95 % CI 1.62-5.22; I 2 = 85.9 %) for adjusted studies. Use of BPs were associated with higher risk on ONJ (OR 2.57; 95 % CI 1.37-4.84; I 2 = 92.2 %) than ON of other sites (OR 1.79; 95 % CI 0.71-4.47; I 2 = 83.3 %). Meta-regression analysis did not find design characteristics or outcome definitions to be significant sources of heterogeneity. Conclusion: The available evidence suggests that use of BPs in cancer patients is associated with a substantial risk for ONJ. Patients receiving IV BP are at highest risk. ? 2013 International Osteoporosis Foundation and National Osteoporosis Foundation. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/526907 | ISSN: | 0937-941X | DOI: | 10.1007/s00198-013-2575-3 | SDG/關鍵字: | bisphosphonic acid derivative; bone density conservation agent; Bisphosphonate-Associated Osteonecrosis of the Jaw; human; meta analysis; methodology; Neoplasms; osteoporosis; procedures; publishing; risk assessment; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Neoplasms; Osteoporosis; Publication Bias; Research Design; Risk Assessment |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。